Syndax Pharmaceuticals Reports Inducement Grants

Biopharmaceutical company grants stock options to new employees under 2023 Inducement Plan

Apr. 3, 2026 at 9:06pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a group of polished, geometric metal and glass objects arranged elegantly on a clean, monochromatic seamless background, conceptually representing the abstract ideas of corporate strategy, finance, and innovation in the biopharmaceutical industry.Syndax Pharmaceuticals' strategic investments in its workforce signal the company's confidence in its future growth and development in the biopharmaceutical industry.NYC Today

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, announced that on April 1, 2026, it granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax.

Why it matters

Syndax's announcement of these inducement grants highlights the company's commitment to expanding its workforce and advancing its pipeline of innovative cancer therapies. Granting equity-based compensation to new hires is a common practice in the biotech industry to attract and retain top talent.

The details

The inducement awards granted by Syndax include stock options to purchase up to 228,500 shares of the company's common stock. These options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on the employees' continued service with Syndax.

  • Syndax granted the inducement awards on April 1, 2026.

The players

Syndax Pharmaceuticals

A commercial-stage biopharmaceutical company advancing innovative cancer therapies, including the FDA-approved menin inhibitor Revuforj® and the FDA-approved monoclonal antibody Niktimvo™.

Got photos? Submit your photos here. ›

The takeaway

Syndax's inducement grants demonstrate the company's commitment to building a strong, talented workforce to support the development and commercialization of its cancer therapies. These types of equity-based incentives are common in the biotech industry as a means of attracting and retaining top talent.